Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

BioRelix enters into antibacterial collaboration with Merck
November 2010
SHARING OPTIONS:

NEW HAVEN, Conn.BioRelix Inc. announced last month that it has entered into a research collaboration agreement with Merck Research Laboratories to identify new antibacterial drug candidates. Under the agreement, BioRelix will apply its riboswitch technology platform to identify compounds with activity against a number of bacterial targets.

The parties will jointly undertake preclinical programs, and Merck will subsequently be responsible for clinical evaluation of any candidates chosen for further development. Merck will pay BioRelix an upfront fee and provide research funding. In addition, BioRelix is eligible to receive payments upon achievement of specified milestones associated with advancement of drug candidates and royalties on the sales of any products derived from the collaboration.
 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.